SENSEX NIFTY
May 24, 2012, 12.45 AM IST | Source: Moneycontrol.com

Aurobindo Pharma gets US FDA nod for generic HIV drug

Aurobindo Pharma on Wednesday said its tentatively approved abbreviated new drug applications for Nevirapine Tablets 200mg and Nevirapine oral suspension have received final approval from US Food and Drug Administration (FDA).

Moneycontrol Bureau

Aurobindo Pharma on Wednesday said its tentatively approved abbreviated new drug applications for Nevirapine Tablets 200mg and Nevirapine oral suspension have received final approval from US Food and Drug Administration (FDA).

Aurobindo's Nevirapine tablets and oral suspension are generic equivalent of Boehringer Ingelheim Pharmaceutical Inc's Viramune tablets and oral suspension. The drug is used as a part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults.

The two products had a market size of about USD 125 million for year ended Dec 2011, the company said, citing IMS Health data.

Aurobindo said both its products have been approved out of Unit III formulations facility in Hyderabad and will launched soon.

It now has 125 final ANDA approvals and 26 tentative approvals  from US FDA.

Aurobindo Pharma shares were up 1.4% at Rs 111.70 on NSE in afternoon trade.

Aurobindo Pharm stock price

On August 22, 2014, Aurobindo Pharma closed at Rs 808.75, down Rs 9.2, or 1.12 percent. The 52-week high of the share was Rs 834.65 and the 52-week low was Rs 171.00.


The company's trailing 12-month (TTM) EPS was at Rs 48.78 per share as per the quarter ended June 2014. The stock's price-to-earnings (P/E) ratio was 16.58. The latest book value of the company is Rs 137.67 per share. At current value, the price-to-book value of the company is 5.87.

Set email alert for

ADS BY GOOGLE

video of the day

See earnings growth spike, big reforms in 2015: Envision

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.